摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

17-cyclopropylmethyl-6,6',7,7'-tetrahydro-4,5α:4',5'α-diepoxy-6,6'-(imino)[7,7'-bimorphinan]3',3,14,14'-tetrol | 155445-75-3

中文名称
——
中文别名
——
英文名称
17-cyclopropylmethyl-6,6',7,7'-tetrahydro-4,5α:4',5'α-diepoxy-6,6'-(imino)[7,7'-bimorphinan]3',3,14,14'-tetrol
英文别名
17-(cyclopropylmethyl)-6,6',7,7'-tetradehydro-4,5α:4',5α'-diepoxy-6,6'-imino-7,7'-bimorphinan-3,3',14,14'-tetrol;(1S,2S,7S,8S,12R,20R,24R,32R)-11-(cyclopropylmethyl)-19,25-dioxa-11,22,33-triazaundecacyclo[24.9.1.18,14.01,24.02,32.04,23.05,21.07,12.08,20.030,36.018,37]heptatriaconta-4(23),5(21),14(37),15,17,26,28,30(36)-octaene-2,7,17,27-tetrol
17-cyclopropylmethyl-6,6',7,7'-tetrahydro-4,5α:4',5'α-diepoxy-6,6'-(imino)[7,7'-bimorphinan]3',3,14,14'-tetrol化学式
CAS
155445-75-3
化学式
C36H37N3O6
mdl
——
分子量
607.706
InChiKey
XLDXIRYFHVJLMK-SZUHWJPHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    45
  • 可旋转键数:
    2
  • 环数:
    12.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    130
  • 氢给体数:
    6
  • 氢受体数:
    8

反应信息

  • 作为反应物:
    描述:
    N,N′-二-Boc-硫脲17-cyclopropylmethyl-6,6',7,7'-tetrahydro-4,5α:4',5'α-diepoxy-6,6'-(imino)[7,7'-bimorphinan]3',3,14,14'-tetrol三乙胺 、 mercury dichloride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 1.0h, 以73%的产率得到tert-butyl (NE)-N-[[(1S,2S,7S,8S,12R,20R,24R,32R)-33-(cyclopropylmethyl)-2,7,17,27-tetrahydroxy-19,25-dioxa-11,22,33-triazaundecacyclo[24.9.1.18,14.01,24.02,32.04,23.05,21.07,12.08,20.030,36.018,37]heptatriaconta-4(23),5(21),14(37),15,17,26,28,30(36)-octaen-11-yl]-[(2-methylpropan-2-yl)oxycarbonylamino]methylidene]carbamate
    参考文献:
    名称:
    Norbinaltorphimine(norBNI)同系物与野生型和突变型mu和kappa阿片受体的结合:药效团的分子识别位点和kappa拮抗剂的组成部分。
    摘要:
    κ阿片拮抗剂norbinaltorphimine(norBNI,1)和κ受体的分子修饰提供了证据,表明如果该配体的N17'质子化胺基团(“地址”)具有非保守的酸性残基,则该配体的选择性是通过离子相互作用实现的。 (Glu297)上的κ受体。在本研究中,我们研究了结构修饰对norBNI类似物对COS-7细胞中表达的野生型和突变型κ和μ阿片受体的亲和力的影响。具有与norBNI相同的拮抗剂药效基团和碱性N17'基团的化合物2、3和7,对野生型κ保持高亲和力,但对突变κ受体(E297K和E297A)的亲和力却大大降低。拮抗药效团的酚或N-取代基团的修饰(4和5)或在地址N17'中心的碱性的去除(6)导致对野生型和突变受体的亲和力大大降低。修饰κ受体后降低的亲和力与κ拮抗剂的质子化的N17′基团(1-3、7)与TM6顶部的E297的羧酸酯基团的离子相互作用一致。与野生型mu受体相比,化合物1-3对
    DOI:
    10.1021/jm000059g
  • 作为产物:
    描述:
    naltrexone 、 noroxymorphone 在 盐酸肼溶剂黄146 作用下, 反应 17.0h, 以51%的产率得到17-cyclopropylmethyl-6,6',7,7'-tetrahydro-4,5α:4',5'α-diepoxy-6,6'-(imino)[7,7'-bimorphinan]3',3,14,14'-tetrol
    参考文献:
    名称:
    Structure-Activity Relationship of N17'-Substituted Norbinaltorphimine Congeners. Role of the N17' Basic Group in the Interaction with a Putative Address Subsite on the .kappa. Opioid Receptor
    摘要:
    A series of norbinaltorphimine congeners (2-12) which contain different groups at the N17'-position have been synthesized in order to evaluate the role of N17' in conferring kappa opioid antagonist selectivity at opioid receptor sites. The compounds that contain a basic N17' nitrogen (2-9) were found to be selective kappa antagonists. Amidation of N17' afforded congeners 10-12 with feeble kappa antagonist potency and low selectivity. The fact that potent antagonism and selectivity were observed only when members of the series contain a basic N17' nitrogen suggests that it interacts with extracellular domains of the kappa receptor that contain acidic amino acid residues. The N-terminal domain and extracellular loop 2, both of which contain acidic residues, are candidates for this interaction and may be components of the kappa address subsite of the receptor.
    DOI:
    10.1021/jm00036a015
点击查看最新优质反应信息